KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) FCF Margin (2016 - 2026)

West Pharmaceutical Services has reported FCF Margin over the past 18 years, most recently at 7.55% for Q1 2026.

  • Quarterly FCF Margin fell 77.0% to 7.55% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 14.73% through Mar 2026, down 550.0% year-over-year, with the annual reading at 15.25% for FY2025, 550.0% down from the prior year.
  • FCF Margin was 7.55% for Q1 2026 at West Pharmaceutical Services, down from 21.74% in the prior quarter.
  • Over five years, FCF Margin peaked at 54.65% in Q4 2022 and troughed at 6.75% in Q3 2024.
  • The 5-year median for FCF Margin is 13.87% (2022), against an average of 17.8%.
  • Biggest five-year swings in FCF Margin: tumbled -3684bps in 2023 and later soared 3683bps in 2024.
  • Tracing WST's FCF Margin over 5 years: stood at 54.65% in 2022, then crashed by -67bps to 17.81% in 2023, then surged by 207bps to 54.65% in 2024, then tumbled by -60bps to 21.74% in 2025, then crashed by -65bps to 7.55% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 7.55%, 21.74%, and 16.64% for Q1 2026, Q4 2025, and Q3 2025 respectively.